Patents Assigned to The United States of America as represented by the Deparment of Veterans Affairs
  • Patent number: 9926360
    Abstract: The present invention provides, in particular embodiments, for modified recombinant T cell receptor (TCR) ligands (RTLs) comprising a MHC class I or MHC class II component. The modified RTLs have redesigned surface features that preclude or reduce aggregation, wherein the modified molecules retain the ability to bind Ag-peptides, target antigen-specific T cells, inhibit T cell proliferation in an Ag-specific manner and have utility to treat, inter alia, autoimmune disease and other conditions mediated by antigen-specific T cells in vivo.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: March 27, 2018
    Assignees: Oregon Health & Science University, The United States of America as represented by the Deparment of Veterans Affairs
    Inventors: Gregory G. Burrows, Arthur A. Vandenbark